Bioimpact Capital LLC is an investment company that specializes in investing in biotechnology companies. BioImpact Capital, in partnership with its affiliate MPM Capital, establishes and supports businesses aimed at tackling urgent unmet medical needs. They invest in biotechnology companies at various stages of development, providing investors the opportunity to participate in both private and public investment opportunities.
Christopher Wolf serves as the Chief Financial Officer at MPM BioImpact. With over 20 years of experience as a CFO at various alternative investment firms, his main role involves supervising the finance operations of the firm. Christopher is actively involved as a member of the Crane Advisory Committee for the Trustees of Reservations and also serves on the Town of Essex Finance Committee. He obtained his B.A. from Williams College and pursued further education, earning his M.S./M.B.A. from Northeastern University.
MPM Bioimpact operates as a hedge fund, serving nine clients with discretionary assets under management amounting to $1,986,654,826 as per Form ADV dated November 2022. Their latest 13F filing for Q4 2023 revealed $427,428,816 in managed 13F securities, with a top 10 holdings concentration of 60.67%. The fund's largest holding is in Cullinan Management Inc., with 7,648,268 shares held.
